Decompression Versus Decompression and Fusion
Launched by MASSACHUSETTS GENERAL HOSPITAL · Sep 2, 2020
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different surgical approaches for treating adjacent segment disease (ASD) in the lower back, which can occur after previous spine surgery. The trial aims to compare the outcomes of a procedure called decompression, which relieves pressure on the nerves, versus a combined approach that includes both decompression and fusion, where the bones are joined together to provide stability. Researchers want to see which method works better for patients who still have symptoms despite trying other treatments for at least six weeks.
To participate in the trial, individuals must be adults aged 65 to 74 who have undergone a previous spine fusion surgery at least a year ago. They should have ongoing issues related to the areas above their previous surgery that haven’t improved with non-surgical treatments. However, those with certain conditions, such as a previous uninstrumented fusion or specific types of instability, will not be eligible. Participants in this trial can expect close monitoring and support throughout the study as they undergo one of the two surgical procedures being tested. This research is important because it aims to provide clearer guidance on the best surgical options for patients dealing with ASD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients at least one year removed from a previous instrumented posterior lumbar fusion
- • Patients with any prior posterior fusion involving L2 to the sacrum, whether single-level or multilevel
- • Patients with symptoms related to central and lateral recess at the supradjacent level that have persisted despite at least six weeks of non-operative therapy modalities
- Exclusion Criteria:
- • Patients with previous uninstrumented lumbar fusions
- • Patients with traumatic, neoplastic, or infectious etiologies at the adjacent segment
- • Patients with prior iliac or sacroiliac fixation and those with nonunion as the primary indication for surgery
- • Patients with pre-existing instability at the supradjacent level. The definition of instability will be determined based on standing lateral, flexion and extension plain radiographs. Patients with \>3mm of change between these views will be excluded.
- • Retrolisthesis will not be a criterion for exclusion
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Daniel Tobert, MD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials